Bioventix PLC (AIM:BVXP)

Market Cap	128.01M
Revenue (ttm)	13.66M
Net Income (ttm)	7.85M
Shares Out	5.22M
EPS (ttm)	1.48
PE Ratio	16.54
Forward PE	n/a
Dividend	1.55 (6.33%)
Ex-Dividend Date	Apr 10, 2025

Volume	1,365
Average Volume	7,362
Open	2,459.00
Previous Close	2,450.00
Day's Range	2,400.00 - 2,500.00
52-Week Range	2,199.00 - 4,200.00
Beta	0.48
RSI	40.94
Earnings Date	Oct 27, 2025

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 17
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In 2024, Bioventix's revenue was 13.61 million, an increase of 6.17% compared to the previous year's 12.82 million. Earnings were 8.10 million, a decrease of -3.29%.